第三代EGFR-TKIs在EGFR敏感突变非小细胞肺癌靶向治疗中的耐药机制及治疗策略研究进展  

Research Progress of Resistance Mechanisms and Therapeutic Strategies of the Third Generation EGFR-TKIs in Non-Small Cell Lung Cancer with EGFR Sensitive Mutation

作　　者：刘媛媛(综述) 王建功(审校)[1] Liu Yuanyuan;Wang Jiangong(First Department of Comprehensive Cancer,Tangshan People’s Hospital,Tangshan 063000,Hebei,China)

机构地区：[1]唐山市人民医院肿瘤综合治疗一科,河北唐山063000

出　　处：《肿瘤预防与治疗》2020年第9期792-798,共7页Journal of Cancer Control And Treatment

基　　金：河北省医学科学研究重点课题计划(编号:20181207)。

摘　　要：肺癌是世界范围内死亡率最高的癌种。一系列表皮生长因子受体酪氨酸激酶抑制剂(epidermal growth factor receptor-tyrosine kinase inhibitors,EGFR-TKIs)的问世,虽然使得部分表皮生长因子受体敏感突变的晚期非小细胞肺癌患者获得了较好的生存获益,但是最终仍不可避免地出现耐药性。本文就第三代EGFR-TKIs的耐药机制及治疗策略研究进展进行综述,为临床提供参考。Lung cancer is the cancer with the highest mortality in the world. With the advent of a series of epidermal growth factor receptor tyrosine kinase inhibitors ( EGFR-TKIs) ,some advanced non-small cell lung cancer patients with epi- dermal growth factor receptor sensitive mutation get better survival benefits. However,drug resistance is still inevitable. This article reviews the research progress of resistance mechanisms and treatment strategies of the third generation EGFR-TKIs,so as to provide experience for clinical practice.

关 键 词：非小细胞肺癌 第三代表皮生长因子受体酪氨酸激酶抑制剂 耐药机制 

分 类 号：R734.2[医药卫生—肿瘤] R730.5[医药卫生—临床医学]